Torrent Pharma Introduces Oral Semaglutide Brands In India

Torrent Pharma has announced the launch of its semaglutide-based therapies under the brand names Sembolic and Semalix. This marks a significant milestone as the company pioneers the introduction of generic oral semaglutide in India, offering patients advanced metabolic care at competitive pricing.  

Product Launch Details  
The new brands are priced from ₹3,999 per month, making them more affordable compared to global alternatives. Oral semaglutide provides a convenient option for patients, eliminating the need for injections and improving adherence to treatment.  

Market Significance  
Semaglutide has gained global recognition for its effectiveness in managing type 2 diabetes and aiding weight loss. Torrent’s entry into this segment positions it strongly within India’s growing metabolic therapy market, where demand for innovative and accessible solutions is rising rapidly.  

Recent Developments  

• Torrent Pharma launches Sembolic and Semalix brands  
• First to introduce generic oral semaglutide in India  
• Pricing starts at ₹3,999 per month  
• Targets diabetes and obesity management with patient-friendly formats  

Future Outlook  
Analysts expect Torrent’s launch to reshape India’s diabetes care landscape. With oral semaglutide offering convenience and affordability, the company is likely to capture significant market share while supporting broader healthcare accessibility.  

Sources: Reuters, Economic Times, Business Standard, Mint